Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Andrew W, Hahn"'
Autor:
Justin R. Gregg, Lisa Newcomb, Ranran Wu, Jennifer Dennison, John W. Davis, Curtis Pettaway, Louis Pisters, John F. Ward, Brian F. Chapin, Lisly Chéry, Ahmet Urkmez, Andrew M. Fang, Noel Higgason, Patricia Troncoso, Carrie R. Daniel, Christopher Logothetis, Timothy C. Thompson, Andrew W. Hahn, Menghan Liu, Yingye Zheng, Dan W. Lin, Samir Hanash, Ehsan Irajizad, Johannes Fahrmann
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-10 (2024)
Abstract Background We previously reported that increases in circulating sphingolipids are associated with elevated risk of biopsy Gleason grade group (GG) upgrading in men on Active Surveillance (AS) for prostate cancer. Here, we aimed to validate t
Externí odkaz:
https://doaj.org/article/9575da14ea9a4934b2c55481192980a8
Autor:
Andrew W. Hahn, Whittney Thoman, Efstratios Koutroumpakis, Amer Abdulla, Sumit K. Subudhi, Ana Aparicio, Karen Basen-Enngquist, Christopher J. Logothetis, Susan C. Gilchrist
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Background Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and receipt of systemic thera
Externí odkaz:
https://doaj.org/article/d9be31932fe64375bddc817b596234b8
Autor:
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang, Apostolia M. Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A. Yap, David S. Hong, Ming Sun, Yunfang Jiang, Shubham Pant, Amishi Y. Shah, Amado Zurita, Nizar M. Tannir, Raghunandan Vikram, Jason Roszik, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-10 (2023)
Abstract Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin a
Externí odkaz:
https://doaj.org/article/0e41dd980da3400cb70f16af34c1c22a
Publikováno v:
Cells, Vol 12, Iss 21, p 2551 (2023)
Immune checkpoint blockade (ICB) is a mainstay of treatment for advanced cancer, yet tumor response and host toxicity are heterogenous in those patients who receive ICB. There is growing interest in understanding how host factors interact with tumor
Externí odkaz:
https://doaj.org/article/d3d00d872c5f4cf4b6a141a3fbea7e05
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Oncologists often refer to forest plots to determine which patient subgroups may be more likely to benefit from a therapy tested in a randomized clinical trial (RCT). We sought to empirically determine the information content of subgroup
Externí odkaz:
https://doaj.org/article/b96d0f1d1c51404fa880ffbd32ad24f6
Autor:
Andrew W. Hahn, Justin Lebenthal, Giannicola Genovese, Kanishka Sircar, Nizar M. Tannir, Pavlos Msaouel
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100640- (2022)
Dedifferentiation in renal cell carcinoma (RCC), either sarcomatoid or rhabdoid, is an infrequent event that may occur heterogeneously in the setting of any RCC histology and is associated with poor outcomes. Sarcomatoid dedifferentiation is associat
Externí odkaz:
https://doaj.org/article/c7b57c73b221438ca018feb03373a2d4
Autor:
Andrew W. Hahn, Stephanie A. Ruderman, Robin M. Nance, Bridget W. Whitney, Sherif Eltonsy, Lara Haidar, Joseph A. C. Delaney, Lydia N. Drumright, Jimmy Ma, Kenneth H. Mayer, Conall O. 'Cleirigh, Sonia Napravnik, Joseph J. Eron, Katerina Christopoulos, Laura Bamford, Edward Cachay, Jeffrey M. Jacobson, Amanda Willig, Karen Cropsey, Geetanjali Chander, Heidi M. Crane, Rob J. Fredericksen
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 92:197-203
Vaporized nicotine (VN) use is increasing among people with HIV (PWH). We examined demographics, patterns of use, depression, and panic symptoms associated with VN and combustible cigarette (CC) use among PWH.We analyzed VN use among PWH in care at 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f59f61585b3812d29e61eb0eea4508df
https://doi.org/10.1097/qai.0000000000003132
https://doi.org/10.1097/qai.0000000000003132
Autor:
Pavlos Msaouel, Nizar M. Tannir, Eric Jonasch, Hung Le, Andrew W Hahn, Omar Alhalabi, Erick Campbell
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background For patients with metastatic renal cell carcinoma (mRCC) who progress on standard-of-care therapies, there is an unmet need for novel treatments. Phase I clinical trials are designed to test the safety, toxicity and optimal dosing of novel
Externí odkaz:
https://doaj.org/article/ef5fcfa477fa46b6a2d537bc3561c46a
Autor:
Stephanie A. Ruderman, Robin M. Nance, Lydia N. Drumright, Bridget M. Whitney, Andrew W. Hahn, Jimmy Ma, Lara Haidar, Sherif Eltonsy, Kenneth H. Mayer, Joseph J. Eron, Meredith Greene, William C. Mathews, Allison Webel, Michael S. Saag, Amanda L. Willig, Charles Kamen, Mary McCaul, Geetanjali Chander, Edward Cachay, William B. Lober, Chintan Pandya, Francisco Cartujano-Barrera, Stephen B. Kritchevsky, Steven N. Austad, Alan Landay, Mari M. Kitahata, Heidi M. Crane, Joseph A.C. Delaney
Publikováno v:
AIDS. 37:967-975
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35dd9ef309e0f6dc29aa83469602e9a9
https://doi.org/10.1097/qad.0000000000003501
https://doi.org/10.1097/qad.0000000000003501
Autor:
Stephanie A. Ruderman, Allison R. Webel, Amanda L. Willig, Lydia N. Drumright, Annette L. Fitzpatrick, Michelle C. Odden, John D. Cleveland, Greer Burkholder, Christine H. Davey, Julia Fleming, Thomas W. Buford, Raymond Jones, Robin M. Nance, Bridget M. Whitney, L. Sarah Mixson, Andrew W. Hahn, Kenneth H. Mayer, Meredith Greene, Michael S. Saag, Charles Kamen, Chintan Pandya, William B. Lober, Mari M. Kitahata, Paul K. Crane, Heidi M. Crane, Joseph A. C. Delaney
Publikováno v:
J Assoc Nurses AIDS Care
Modifications to Fried’s frailty phenotype (FFP) are common. We evaluated a self-reported modified frailty phenotype (Mod-FP) used among people with HIV (PWH). Among 522 PWH engaged in two longitudinal studies, we assessed validity of the four-item
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804fb921f2ca64a01b47da3e43d04895
https://doi.org/10.1097/jnc.0000000000000389
https://doi.org/10.1097/jnc.0000000000000389